Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Sutro Biopharma's Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• In Q4 2025, Depreciation & Amortization (CF) fell 14.35% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $7.3 million (up 1.14% YoY), while the FY2025 annual figure was $7.3 million, up 1.14% from the prior year.
• Depreciation & Amortization (CF) came in at $1.6 million for Q4 2025 at Sutro Biopharma, down from $1.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q1 2025 to a low of $1.1 million in Q3 2021.
• A 5-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) increased 28.62% in 2022 and declined 14.35% in 2025, its largest moves.
• Sutro Biopharma's Depreciation & Amortization (CF) stood at $1.3 million in 2021, then climbed by 21.01% to $1.5 million in 2022, then increased by 12.55% to $1.7 million in 2023, then grew by 7.91% to $1.9 million in 2024, then retreated by 14.35% to $1.6 million in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.6 million, $1.9 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison